4//SEC Filing
Burak Eric 4
Accession 0000899243-21-005321
CIK 0001805890other
Filed
Feb 7, 7:00 PM ET
Accepted
Feb 8, 9:05 PM ET
Size
14.7 KB
Accession
0000899243-21-005321
Insider Transaction Report
Form 4
Burak Eric
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-02-04+139,000→ 139,000 totalExercise: $11.90Exp: 2031-02-03→ Common Stock (139,000 underlying) - Award
Stock Option (Right to Buy)
2021-02-04+136,600→ 136,600 totalExercise: $11.90Exp: 2031-02-03→ Common Stock (136,600 underlying) - Award
Stock Option (Right to Buy)
2021-02-04+41,000→ 41,000 totalExercise: $11.90Exp: 2031-02-03→ Common Stock (41,000 underlying)
Footnotes (3)
- [F1]25% of the shares subject to this option shall vest and become exercisable on February 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
- [F2]The shares subject to this option shall vest and become exercisable in 36 substantially equal monthly installments beginning one month after the Transaction Date.
- [F3]The shares subject to this option vest and become exercisable upon the achievement of certain manufacturing and development milestones; such milestones are expected to occur between December 2022 and December 2026.
Issuer
Fusion Pharmaceuticals Inc.
CIK 0001805890
Entity typeother
Related Parties
1- filerCIK 0001813701
Filing Metadata
- Form type
- 4
- Filed
- Feb 7, 7:00 PM ET
- Accepted
- Feb 8, 9:05 PM ET
- Size
- 14.7 KB